ストックスクリーナーアプリを入手
2.33
3.72%
-0.09
前日終値:
$2.42
開ける：
$2.37
24時間の取引高:
10,648
Relative Volume:
0.30
時価総額：
$36.10M
収益：
$22.06M
当期純損益:
$-30.94M
株価収益率:
-1.0402
EPS:
-2.24
ネットキャッシュフロー:
$-26.70M
1週間 パフォーマンス:
-7.72%
1か月 パフォーマンス:
-12.41%
6か月 パフォーマンス:
-63.88%
1年 パフォーマンス:
-58.02%
1日の値動き範囲:
$2.2633
$2.42
1週間の範囲:
$2.2633
$2.5206
52週間の値動き範囲:
$2.05
$7.67
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
CASI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
2.33 | 36.10M | 22.06M | -30.94M | -26.70M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 開始されました | Mizuho | Buy |
| 2020-10-23 | 開始されました | Oppenheimer | Outperform |
| 2016-09-22 | 開始されました | Maxim Group | Buy |
| 2015-10-29 | 再開されました | H.C. Wainwright | Buy |
| 2015-06-23 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Casi Pharmaceuticals Inc (CASI) 最新ニュース
StockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated at StockNews.com - Defense World
Hypoxia Treatment Market to Witness Substantial Growth by 2031 | - openPR
CASI Pharmaceuticals (NASDAQ:CASI) Research Coverage Started at StockNews.com - Defense World
Multiple Myeloma Clinical and Non-Clinical Studies, Key - openPR
CASI Pharmaceuticals Secures Interim Relief in Juventas Dispute - TipRanks
Critical Comparison: Biora Therapeutics (NASDAQ:BIOR) versus CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) Secures EU Patent for FHAB Platform Technology - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com - Defense World
Multiple Myeloma Pipeline 2024: FDA Approvals, Therapies, - openPR
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - ACCESS Newswire
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - ACCESS Newswire
CASI Pharmaceuticals Faces Asset Freezing Amid Arbitration Dispute - TipRanks
Assenagon Asset Management S.A. Increases Stock Holdings in Premier, Inc. (NASDAQ:PINC) - Defense World
Can this 10.8% yield from a FTSE 250 share last? - Yahoo Finance UK
CASI Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Marketscreener.com
CASI Pharmaceuticals Launches Pivotal Phase 1/2 Trial for Novel ITP Treatment CID-103 - StockTitan
Major 2024 licensing deals confirm Asia’s ascent from copier to innovator - BioWorld Online
CASI Pharmaceuticals, Inc. Announces Clinical Hold of CID-103 for Antibody Mediated Rejection of Kidney Transplant - Marketscreener.com
CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA - TipRanks
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - The Eastern Progress Online
Is a stock market crash coming? And what should I do now? - Yahoo Finance UK
CASI Pharmaceuticals Faces Evomela® License Termination Dispute - TipRanks
Pre-market Movers: SXTC, STIM, BIOA, UPC... - RTTNews
The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34% - Simply Wall St
CASI Pharmaceuticals Insider Ups Holding By 65% During Year - Simply Wall St
CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q3 Revenue $7.8M - Marketscreener.com
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CASI Pharma Q3 Revenue Jumps 96% QoQ to $7.8M Despite Wider Losses, Advances Pipeline | CASI Stock News - StockTitan
CASI Pharmaceuticals Inc (CASI) Quarterly 10-Q Report - Quartzy
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - GuruFocus.com
(CASI) Proactive Strategies - Stock Traders Daily
CASI Pharmaceuticals gets China nod for ITP treatment trial - Investing.com
CASICASI Pharmaceuticals, Inc. Ordinary Shares Latest Stock News & Market Updates - StockTitan
CASI Pharmaceuticals, Inc. Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - Marketscreener.com
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
CASI Pharmaceuticals gets China nod for ITP treatment trial By Investing.com - Investing.com Nigeria
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Update - MarketBeat
Objective long/short (CASI) Report - Stock Traders Daily
Renaissance Technologies LLC Acquires 4,000 Shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) - Defense World
(CASI) Trading Report - Stock Traders Daily
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200 Day Moving Average of $4.67 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average of $4.67 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still up 129% over 1 year despite pulling back 22% in the past week - Yahoo Finance
Casi Pharmaceuticals Inc (CASI) 財務データ
収益
当期純利益
現金流量
EPS
0.53%
0.33%
大文字化:
|
ボリューム (24 時間):